FDA panel votes against EDAP’s ultrasound prostate cancer ablation

July 31, 2014 By Ingrid Mezo Leave a Comment

FDA panel rejects EDAP's ultrasound prostate cancer ablation

The FDA’s Gastroenterology & Urology Devices panel today voted against recommending approval of EDAP’s (NSDQ:EDAP) Ablatherm system for thermal ablation of the prostate gland to treat low-risk, localized prostate cancer.

The panel unanimously voted against Ablatherm’s effectiveness, in majority against the device’s safety (5 no votes, 3 yes votes and 1 abstention) and against its benefits outweighing its risks (8 no votes and 1 abstention).

Ablatherm is a computer-controlled high intensity focused ultrasound (HIFU) medical device that delivers treatment from an endorectal probe under ultrasound visualization and is intended to ablate the entire prostate gland, according to FDA background materials released ahead of the meeting.

While panelists admired the technology used by Ablatherm, they found fault with the study design and the primary endpoint used to demonstrate its effectiveness in the trial. EDAP compared 2-year biochemical survival rates for patients treated with Ablatherm to a performance goal derived from cryotherapy literature. The panel said that this was not adequate to show that the device is effective, saying that prostate cancer is often a slow-developing disease that can take up to 20 years to pose a mortality risk.

They also noted high rates of adverse events associated with Ablatherm, including erectile dysfunction and urinary incontinence, clinically significant rates of stricture, urethral injury and bowel injury.

Prostate cancer is the second most common cause of cancer-related death in U.S. men and is now the leading cause of soft tissue malignancy in men, representing 1/3rd of incident cancer cases, the federal watchdog agency noted. Prostate cancer accounts for 3% of all male deaths.

Among patients diagnosed with the disease, 46% are reported as being at low risk, 30% at moderate risk, and 24% at high risk, according to the D’Amico classification. Due to the widespread use of PSA screening in clinical practice, more men are being diagnosed at earlier stages and thus have a lower risk of morbidity and mortality from the disease, the FDA pointed out.

There are currently no legally marketed HIFU devices to treat prostate cancer and men with localized prostate cancer are treated either aggressively with radical prostatectomy surgery or radiation or more conservatively with regular monitoring with delayed therapy when warranted. Cryotherapy and hormone therapy are also used on occasion to battle prostate cancer.

There is increasing evidence that therapeutic intervention delays disease progression and disease-specific mortality as compared to active surveillance (no treatment) but has little or no effect on overall survival regardless of risk strata, the FDA noted.

Despite this, the majority of patients with low-risk prostate cancer still undergo therapeutic intervention either initially or after a relatively short period of active surveillance. Though "no treatment" might be an acceptable option for low risk disease in patients with limited life expectancy, it is widely accepted that there is currently no definitive way to determine which men require treatment and who can be safely managed on active surveillance, the agency said.

5 tips to raise funding for your medical device
Securing funding can be a long and tedious process, and medical device businesses must work to position themselves as especially attractive to potential investors to maximize success and accelerate the fundraising process. Jon Speer, Greenlight Guru According to Alejandro Cremades, author of The Art of Startup Fundraising, it can take from six to nine months… […]
FDA recognizes latest ISO 14971 as medical device consensus standard
By Mark Leimbeck and Stewart Eisenhart, Emergo Group The US Food and Drug Administration has granted Recognized Consensus Standard status to the third edition of the ISO 14071 risk management standard for medical devices and IVD products. Get the full story here at the Emergo Group’s blog. The opinions expressed in this blog post are… […]
Synaptive Medical updates Modus V surgical microscope
Synaptive Medical announced that its U.S. and Canadian Modus V robotic digital microscope now includes updates such as additional 3D visualization and voice-activated control. The Modus V is a robotically controlled digital microscope used as part of Synaptive’s BrightMatter surgical suite designed for less invasive, patient-specific approaches in complex cranial procedures. The Modus V provides similar… […]
New machine can preserve donor livers for 1 week
Researchers in Switzerland have built a perfusion machine that can preserve human livers for transplantation for a week or more, potentially slashing the number of donor livers that must be discarded due to time-related deterioration. Existing perfusion technology can preserve a donor liver for up to 24 hours. The team of surgeons, biologists and engineers… […]
Smiths Medical launches Portex tracheostomy tubes and kits
Smiths Medical this week launched its Portex polyvinyl chloride tracheostomy tube and kit portfolio. The new polyvinyl chloride (PVC) tube portfolio has options for a variety of patients, according to the company. “Our goal was to create tracheostomy tubes and kits designed to help clinicians provide the best patient care. We’re excited to offer a variety… […]
FDA clears Cleveland Clinic 3D-printed airway stents
The FDA recently cleared 3D-printed, patient-specific stents developed by a doctor at the Cleveland Clinic. Cleveland Clinic physician Tom Gildea developed the stents to keep open the airways of patients with serious breathing disorders caused by inflammation, trauma, tumors and other masses. Airway stents come in a limited number of sizes and shapes and are… […]
Boston Scientific shares drop on Q4 sales news
Shares in Boston Scientific (NYSE:BSX) dropped 8% this morning on news of disappointing fourth-quarter sales. The company’s preliminary earnings report showed sales for the quarter ended Dec. 31, 2019 coming in at $2.9 billion, below the $2.91 billion that analysts were expecting. The unaudited sales figure represents organic growth of 7.3%, missing the company’s own guidance of… […]
Study: Timing for knee replacement surgeries is off
New research from Northwestern Medicine suggests that patients with knee osteoarthritis are having knee surgery at the wrong time. According to the researchers, 90% of patients who could benefit from knee replacement surgery are waiting too long to have it and 25% of patients who don’t need it are having it prematurely. “People are waiting… […]
TransEnterix wants to use more AI in surgical robotics: Here’s how
TransEnterix (NYSE:TRXC) has filed a 510(k) submission to add an artificial intelligence feature to its robot-assisted surgery system in which the system can automatically move the camera for a surgeon. Surgeons have been able to move the camera on TransEnterix’s Senhance System via eye sensing. But the new Intelligent Surgical Unit would allow a surgeon, for… […]
Diversified Plastics names Kieval to board
Diversified Plastics, a custom plastic-injection molder and digital thermoplastic components manufacturer, said today that it has appointed Robert Kieval to its board of directors. Kieval has more than 25 years of experience at all levels of the medtech industry. The CEO of IMMR, Inc., Kieval previously served as chief scientific and clinical officer at women’s… […]
Micro celebrates 75 years in business
Contract manufacturer Micro (Somerset, N.J.) this week announced its 75th anniversary in business. Founded in 1945 as Micro Stamping Corp. in Maplewood, N.J., the family-owned company specializes in precision medical components, sub-assemblies and complete devices for laparoscopic surgical procedures. Operations have expanded from 28,000-square feet to nearly 180,000-square feet, and the company recently dedicated an… […]